Skip to content
Research Article Open access CC BY 3.0

Pharmacovigilance Analysis of Adverse Psychiatric Events and Suicidality Reported for Roflumilast, an Add-On COPD Therapy

Ayad K. Ali

Journal of Pharmaceutical Research International · pp. 972–982 · Published 21 Aug 2013

10.9734/BJPR/2013/5633

Abstract

Aims: Roflumilast is a phosphodiesterase-4-inhibitor used as add-on therapy to long-acting bronchodilators in chronic obstructive pulmonary disease. Although roflumilast is well tolerated, there have been concerns regarding psychiatric problems, including suicide tendencies. This study aims to identify and characterize signals of adverse psychiatric events reported for roflumilast in the US FDA Adverse Event Reporting System (FAERS). Study Design: Retrospective pharmacovigilance analysis. Place and Duration of Study: Adverse event reports submitted to FAERS from October 1997 through September 2012. Methodology: Multi-item Gamma Poisson Shrinker data-mining algorithm was applied to adverse psychiatric events (APE) that were submitted to the FAERS (3Q1997-3Q2012). Empirical Bayes Geometric Mean (EBGM) and 95% confidence interval (EB05-EB95) were calculated for roflumilast-associated APE compared to all drugs in FAERS. The following Preferred Terms of the MedDRA terminology were used to define the outcome of interest: “anxiety”, “depressed mood”, “depression”, “insomnia”, “suicide attempt”, and “suicidal ideation”. Signals with EB05>2 are considered significant disproportional reporting (>twice that expected) of APE. Results:126 reports of APE were identified for roflumilast, corresponding to mutually non-exclusive events of insomnia (n=53), anxiety (n=38), depression (n=36), suicidal ideation (n=30), depressed mood (n=8), and suicide attempt (n=6). EBGM (EB05-EB95) were: APE, 3.55 (3.06-4.11); insomnia, 4.55 (3.62-5.66); anxiety, 2.96 (2.26-3.82); depression, 2.88 (2.19-3.75); suicidal ideation, 5.65 (4.16-7.52); depressed mood, 3.90 (2.20-6.53); and suicide attempt, 1.66 (0.86-2.95). Conclusion: Roflumilast is associated with higher than expected reporting of APE, including suicidal thoughts, but not suicide attempts. Given the inherent confounding and bias limitations of spontaneous reporting systems, pharmacoepidemiologic studies are required to test these hypotheses; meanwhile, prescribers should consider alternative add-on therapies to patients with past or present depression or suicidality.

Roflumilast Adverse Event Reporting System FAERS Suicide Psychiatric Events COPD Pharmacovigilance

References (8)

  1. 1 Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease [DOI]
  2. 2 Roflumilast: first phosphodiesterase 4 inhibitor approved for treatment of COPD [DOI]
  3. 3 Phosphodiesterase-4 Inhibitor Therapy for Lung Diseases [DOI]
  4. 4 Depression in COPD ? management and quality of life considerations [DOI]
  5. 5 Roflumilast: A Phosphodiesterase-4 Inhibitor for the Treatment of Severe Chronic Obstructive Pulmonary Disease [DOI]
  6. 6 Is COPD associated with suicide behavior? [DOI]
  7. 7 Pharmacovigilance analysis of adverse event reports for aliskiren hemifumarate, a first-in-class direct renin inhibitor [DOI]
  8. 8 Positive association between the plasma levels of 5-hydroxyindoleacetic acid and the severity of depression in patients with chronic obstructive pulmonary disease [DOI]

Cited by 8

Signal Detection and Clarification of Peripheral Neuropathy and Guillain-Barré Syndrome Associated with Exposure to Systemic Fluoroquinolones

Ayad K. Ali · Journal of Pharmaceutical Research International · 2013

Peripheral neuropathy and Guillain-Barré syndrome risks associated with exposure to systemic fluoroquinolones: a pharmacovigilance analysis

Ayad K. Ali · Annals of Epidemiology · 2014

Prescribed Drugs and Self-Directed Violence: A Descriptive Study in the Spanish Pharmacovigilance Database

Ana Avedillo-Salas, Javier Pueyo-Val, Ana Fanlo-Villacampa · Pharmaceuticals · 2023

A real-world disproportionality analysis of roflumilast using the US food and drug administration adverse event reporting system data

Baiqing Huang, Yirou Ma, Wenli Wang · Frontiers in Drug Safety and Regulation · 2025

Showing 4 of 8 known citations — external sources report more than can currently be individually listed.

Related research

Article metrics

Real usage data collected on this platform.

43

Page views

0

PDF downloads

6

Outbound clicks

8

Citations

Views over time

Views by country

Approximate, from request IP at view time — not citizenship or institution. Countries with fewer than 5 views are grouped as "Other".

Traffic sources

Referring site, by host.

Views and downloads exclude known bots/crawlers. Citations combines this platform's own DOI-resolved index with each external source's own reported total — see Cited by above for individually listed citing works. Last refreshed 0 seconds ago.